Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1954 1
1955 1
1957 3
1959 3
1960 1
1961 1
1962 4
1963 4
1964 3
1965 1
1966 4
1967 1
1968 3
1969 2
1970 3
1972 4
1973 2
1974 2
1975 1
1976 1
1977 2
1979 2
1981 1
1982 4
1983 4
1984 3
1985 6
1986 5
1987 1
1988 4
1989 3
1990 4
1991 2
1992 4
1993 2
1994 2
1997 2
1998 3
1999 3
2001 1
2002 4
2003 5
2004 4
2005 3
2006 2
2007 2
2008 6
2009 6
2010 6
2011 5
2012 7
2013 7
2014 8
2015 6
2016 6
2017 6
2018 15
2019 6
2020 7
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

213 results
Results by year
Filters applied: . Clear all
Page 1
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cross DA, et al. Among authors: orme jp. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3. Cancer Discov. 2014. PMID: 24893891 Free PMC article.
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M. Durant ST, et al. Among authors: orme j. Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun. Sci Adv. 2018. PMID: 29938225 Free PMC article.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. Orme JJ, et al. Oncoimmunology. 2020 Apr 14;9(1):1744980. doi: 10.1080/2162402X.2020.1744980. eCollection 2020. Oncoimmunology. 2020. PMID: 32363112 Free PMC article.
Hyperbaric oxygen for acute carbon monoxide poisoning.
Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott CG, Clemmer TP, Orme JF Jr, Thomas FO, Morris AH. Weaver LK, et al. Among authors: orme jf jr. N Engl J Med. 2002 Oct 3;347(14):1057-67. doi: 10.1056/NEJMoa013121. N Engl J Med. 2002. PMID: 12362006 Free article. Clinical Trial.
Editorial.
Orme J, Pilkington P, Hills S, Longhurst J, Grant M. Orme J, et al. Health Educ Res. 2010 Jun;25(3):381-2. doi: 10.1093/her/cyq026. Health Educ Res. 2010. PMID: 20484143 No abstract available.
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. Floc'h N, et al. Among authors: orme jp. Mol Cancer Ther. 2018 May;17(5):885-896. doi: 10.1158/1535-7163.MCT-17-0758. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483211 Free PMC article.
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N, Lim S, Bickerton S, Ahmed A, Orme J, Urosevic J, Martin MJ, Cross DAE, Cho BC, Smith PD. Floc'h N, et al. Among authors: orme j. Mol Cancer Ther. 2020 Sep 17. doi: 10.1158/1535-7163.MCT-20-0103. Online ahead of print. Mol Cancer Ther. 2020. PMID: 32943544
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. Finlay MR, et al. Among authors: orme jp. J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1. J Med Chem. 2014. PMID: 25271963
213 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page